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Post-zygotic Point Mutations Are an Underrecognized
Source of De Novo Genomic Variation
Rocio Acuna-Hidalgo,1 Tan Bo,2 Michael P. Kwint,1 Maartje van de Vorst,1 Michele Pinelli,3
Joris A. Veltman,1,4 Alexander Hoischen,1,5,* Lisenka E.L.M. Vissers,1,5 and Christian Gilissen1,5
De novo mutations are recognized both as an important source of genetic variation and as a prominent cause of sporadic disease in hu-
mans. Mutations identified as de novo are generally assumed to have occurred during gametogenesis and, consequently, to be present as
germline events in an individual. Because Sanger sequencing does not provide the sensitivity to reliably distinguish somatic from germ-
line mutations, the proportion of de novo mutations that occur somatically rather than in the germline remains largely unknown. To
determine the contribution of post-zygotic events to de novo mutations, we analyzed a set of 107 de novo mutations in 50 parent-
offspring trios. Using four different sequencing techniques, we found that 7 (6.5%) of these presumed germline de novo mutations
were in fact present as mosaic mutations in the blood of the offspring and were therefore likely to have occurred post-zygotically.
Furthermore, genome-wide analysis of ‘‘de novo’’ variants in the proband led to the identification of 4/4,081 variants that were also
detectable in the blood of one of the parents, implying parental mosaicism as the origin of these variants. Thus, our results show
that an important fraction of de novo mutations presumed to be germline in fact occurred either post-zygotically in the offspring or
were inherited as a consequence of low-level mosaicism in one of the parents.Introduction
In humans, DNA replication is estimated to entail one er-
ror in every 108 base pairs, giving rise to 30–100 genome-
wide de novo mutations in each new generation.1–3
Whereas neutral or benign de novo point mutations
contribute to normal genetic variation, single detrimental
de novo mutations have been established to cause a num-
ber of rare developmental disorders4–6 and are increasingly
recognized as a major contributor to common sporadic dis-
orders, such as intellectual disability (ID) and autism.7,8 De
novo mutations are thought to occur predominantly in
the egg or sperm cell and thus result in an embryo with a
constitutive mutation. However, de novo mutations can
also appear post-zygotically, leading to embryonic mosai-
cism, a state in which two or more genetically distinct
cell populations in an individual develop from a single
fertilized egg.
Several reports have shown a high frequency of mosai-
cism for copy-number variations (CNVs) from cleavage-
stage embryos9 to fully differentiated tissues.10–12 Simi-
larly, there is increasing evidence of a high prevalence
of mosaicism for single-nucleotide variants (SNVs) as a
result of mutations appearing from early embryogenesis
onward13,14 and throughout adult life.15,16 Currently,
post-zygotic de novo mutations receive growing atten-
tion in developmental diseases.17–19 The timing of the
event plays a key role in the clinical phenotype by deter-
mining not only the proportion of affected cells in the
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Thits pervasiveness, however, the true extent of mosaicism
for SNVs remains unclear. This is largely a consequence
of the technological limitations to accurately detecting
these mutations; on one side, mutations with low levels
of mosaicism are often below the threshold of sensitivity
and specificity for automated and systematic detection of
traditional sequencing methods,20 and on the other
hand, mutations with a higher percentage of affected
cells are easily detected by traditional sequencing
methods, but it remains technically challenging to differ-
entiate them from germline de novo mutations. Indeed,
to discriminate post-zygotic from germline de novo mu-
tations by sequencing DNA, it is crucial to distinguish
biologically relevant allele imbalances from technical
artifacts.
To gain insight into the frequency of post-zygotic events
among de novo mutations, we performed a systematic
evaluation of de novo mutations identified by trio-based
whole-genome sequencing (WGS) of 50 individuals with
severe ID and their parents. Previous analysis of WGS
data from this cohort recently pointed to germline de
novo mutations as the major cause of ID in the affected in-
dividuals.21 Additionally, these data indicated the presence
of de novo mutations of somatic origin.21 By systemati-
cally assessing allelic ratios by various sequencing tech-
niques, we show here that a proportion of previously
reported de novo mutations did not occur during gameto-
genesis but, in fact, arose as post-zygotic events in the pro-
band or were present as low-level somaticmutations in one
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Material and Methods
Defining a Set of De Novo Mutations from WGS of
Parent-Proband Trios
This study was performed in accordance with the ethical stan-
dards of the Medical Ethics Committee of the Radboud University
Medical Center. All participants or their legal representatives gave
informed consent. WGS of 50 parent-proband trios and subse-
quent de novo mutation detection were performed as described
previously.21 In brief, trio-based WGS was performed by Com-
plete Genomics (CG) at 80-fold coverage. Sequence reads were
mapped to the reference genome (UCSC Genome Browser
hg19), and variants were called with CG software v.2.4. De
novo mutations were called with CG’s cgatools calldiff program,
which detects the differences between the genotypes of two sam-
ples and assigns a somatic score on the basis of sequencing qual-
ity and comparison of paired samples. Mutations whose scores
comparing offspring to each parent were R5 were called as
high-confidence de novo mutations (a total of 4,081 were de-
tected in the 50 trios). The original report identified a set of
127 de novo mutations affecting either genome-wide coding
sequence or specifically the non-coding sequence of known ID-
associated genes.21 This set served as the starting point for the
current study.
Sequencing Methods Used for Assessing the Post-
zygotic State of De Novo Mutations
PCR amplicons for amplicon-based deep sequencing (ADS) and
Sanger sequencing were generated according to standard PCR pro-
tocols. ADS was performed on an Ion Torrent Personal Genome
Machine (Life Technologies) as described previously.21 In brief,
raw sequencing reads were mapped to the reference genome
with the Burrows-Wheeler Aligner (BWA), and the alignment files
were then analyzed in the Integrative Genomics Viewer (IGV).22
For Sanger sequencing, PCR products were sequenced after enzy-
matic clean up.
Sequencing using single-molecule molecular inversion probes
(smMIPs) was performed according to previously published proto-
cols.23 In brief, smMIPs targeting the selected de novo mutation
and a total of 112 bp of surrounding sequence were designed
in house and ordered from Integrated DNA Technologies. The
smMIPs were pooled and phosphorylated, after which the
genomic regions of interest were captured with the probes and
amplified. Sequencing was performed on theNextSeq 500Desktop
Sequencer (Illumina), and the reads were aligned with our in-
house bioinformatics pipeline for analysis of molecular inversion
probes. Through the use of molecular barcodes, we were able to re-
move PCR duplicates. Read counts for the positions of interest
were extracted from the alignment files through IGV.
Assessment of the Allelic-Ratio Distribution of True
Heterozygous Variants
To define the parameters of technical variation in WGS, ADS, and
Sanger sequencing, we determined for each technology the allelic
ratio of inherited SNVs as a proxy for true heterozygousmutations.
The allelic ratio was defined as the proportion of variant reads
from the total number of sequencing reads covering a given base
pair and is expressed here as a percentage. We established the dis-
tribution of the allelic ratio for true heterozygous variants in WGS
data by determining the allelic ratio of 115 inherited SNVs (cod-
ing, synonymous variants absent from dbSNP138 or present at a68 The American Journal of Human Genetics 97, 67–74, July 2, 2015frequency below 1.5%) from WGS data of a single individual. To
minimize the risk of false-positive variant calls, we used a second
independent set of 109 inherited SNVs to determine the distribu-
tion of the allelic ratio in ADS and Sanger sequencing. This set was
randomly selected from a larger set of 442 rare, coding variants
inherited from either parent in ten probands, and variants were
selected to have a coverageR 20-fold in WGS and an allelic ratio
between 40% and 60%. Variants on the X chromosome and/or
located in established disease-associated genes were excluded.
For ADS experiments, after mapping with the BWA, variants
were visualized with the IGV, and allelic ratios were determined
by assessment of the number of total reads and each respective
base at this position. For Sanger sequencing, the chromatogram
trace files were visualized with Vector NTI (Life Technologies),
and intensities per dye per variant base were used for calculating
the allelic ratio.Identification of Post-zygotic Events in Probands
A set of 127 de novo mutations identified by WGS were re-
sequenced by ADS and Sanger sequencing. For 107 (84%) of these
variants, allelic ratios could be determined for all three sequencing
techniques. We calculated the individual Z score per method for
each mutation by using the values from sequencing heterozygous
variants with each sequencing method as a reference. To calculate
Z scores, we first obtained the difference between the allelic ratio
and the mean allelic ratio and then divided that by the SD for het-
erozygous variants on that sequencing technique. Subsequently,
we combined these scores into a single Z score for each de novo
mutation by summing the individual Z scores and dividing this to-
tal by the square root of the number of scores. The critical value for
statistical significance was established as 0.05 after Benjamini-
Hochberg correction for multiple testing. To exclude amplification
bias as the cause of a deviation in the allelic ratio, we re-sequenced
de novo SNVs with a statistically significant combined Z score by
ADS with a second independent primer pair. Finally, we used
smMIPs as an independent technique to validate the presence of
these variants as mosaic mutations (a set of seven heterozygous
mutations served as a reference).Identification of Parental Mosaicism in WGS Data
To detect low-level parental mosaicism for SNVs mimicking germ-
line de novo mutations in the child, we re-analyzed the WGS data
of the 50 parent-offspring trios. To this end, we used all 4,081
high-confidence candidate de novo mutations identified in the
probands, because these have previously been shown to have a
de novo validation rate of 78%.21 We then filtered for de novo var-
iants for which at least two reads carrying the same mutation in
the raw sequencing data were found in either one of the parents.
We sequenced the position of interest by ADS in the DNA of the
transmitting parent to validate parental mosaicism for the remain-
ing 11 mutations. We established the position-specific sequencing
error rate by sequencing the same position by ADS in the DNA of
the non-transmitting parent in an independent sequencing run
to avoid any contamination or barcode bleed-through. Then, the
fraction of reads showing a non-reference allele at the correspond-
ing base pair was calculated. The presence of the variant as a
mosaic mutation in the transmitting parent was confirmed if the
proportion of variant reads for the position and nucleotide of
interest was significantly higher than the sequencing error estab-
lished for that base-pair position from the non-transmitting
parent.
Figure 1. Workflow for the Detection of Mosaic Mutations among a Subset of Apparently De Novo Mutations
(A) Assessment of technique-dependent variation in sequencing of two groups of heterozygous germline variants (in blue) for deter-
mining the distribution of allelic ratios for three different techniques (WGS, ADS, and Sanger sequencing).
(B) Previously identified de novo mutations were re-sequenced by ADS and Sanger sequencing for determining the variant ratio. With
the use of the combined Z score, nine putative somatic variations were identified. They were then validated by ADS with a second in-
dependent primer pair and smMIPs. Seven of nine were confirmed to deviate in allelic ratio, suggesting a non-germline event.
(C) Identification of de novomutations originating from parental mosaicism. Of 4,081 high-confidence de novomutations identified by
WGS, 13 were identified to have two or more variant reads in parental DNA. With the use of ADS data from the non-carrier parent for
correcting for the background sequencing error, four mutations appearing as de novo in the child were identified as low-level mosaicism
in one of the parents.Computational Modeling of Sequencing Coverage for
the Identification of Mosaicism
To assess the ability of identifying mosaic variants from
sequencing data, we simulated the effect of sequencing coverage
on variant identification for different levels of mosaicism. To
distinguish low-level mosaicism from sequencing artifacts, we
assumed that automated variant-calling algorithms require the
variant to be present in R5 sequencing reads and constitute
R5% of the total number of reads at the position of interest.
We used a binomial distribution to calculate the probability
of reaching both these requirements for different depths of
coverage and various levels of mosaicism. Assuming that a
mosaic variant is identified, we also modeled the deviation of
the allelic ratio from 50% (representing true heterozygosity),
which is necessary for distinguishing a mosaic from a germline
variant. Reads for heterozygous variants at different sequencing
depths were simulated (n ¼ 10,000) on the basis of a binomial
distribution. We calculated the SD of this distribution and the
level of mosaicism at which a mosaic variant could be reliably
distinguished from a heterozygous variant for different thresh-
olds of significance. Lastly, we determined the sequence coverage
required for identifying low-level parental mosaicism. In this
case, the position of interest was readily identified because theThoffspring presented with an apparently de novo mutation at
this position. For this, we considered that at least two variant
reads were sufficient for distinguishing the variant from a back-
ground sequencing error. Finally, we applied a binomial model
for different sequencing depths and levels of mosaicism to
calculate the probability of obtaining two variant reads in the
sequencing data.Results
Determining the Technical Variation for WGS, ADS,
and Sanger Sequencing
In this study, we set out to distinguish mosaic mutations
from true germline de novo mutations (Figure S1) by
sequencing. To gain insight into the sensitivity of WGS,
ADS, and Sanger sequencing, we re-sequenced two
different sets of inherited germline mutations as a proxy
for true heterozygosity (Figure 1A and Figure S2). We sub-
sequently determined the distribution of the allelic ratios
per technology (Table S1 and Figure S3). With an allelic ra-
tio of 48.25 4.4% (average5 SD), ADS showed to be thee American Journal of Human Genetics 97, 67–74, July 2, 2015 69
Table 1. De Novo Mutations Occurring as Post-zygotic Events in Offspring
Gene
OMIM Accession
Number
Mutation at gDNA
Level (hg19) Location
Predicted Mutation at cDNA Level
(GenBank Accession Number)
Predicted Protein
Substitution p Valuea
Average
Allelic Ratio
KANSL2 615488 chr12:49072911C>A exon 4 c.453G>T (NM_017822.3) p.( ¼ ) 6.94E21 20.8%
CREBL2 603476 chr12:12788868G>C exon 2 c.173G>C (NM_001310.2) p.Arg58Pro 6.40E19 21.0%
PIAS1 603566 chr15:68468014T>A exon 10 c.1209T>A (NM_016166.1) p.Asp403Glu 1.84E18 22.9%
PNKP 605610 chr19:50367525C>T intron 5 c.57932G>A (NM_007254.3) NA 7.05E17 22.7%
HIVEP2 143054 chr6:143092683C>T exon 5 c.3193G>A (NM_006734.3) p.Ala1065Thr 2.20E14 25.2%
DPYD 274270 chr1:97588236C>T intron 21 c.262324048G>A (NM_000110.3) NA 3.17E10 29.7%
NEK1 604588 chr4:170359295T>G exon 27 c.2703A>C (NM_001199397.1) p.Lys901Asn 3.67E08 29.4%
The following abbreviation is used: NA, not applicable.
ap values were corrected by Benjamini-Hochberg for multiple testing. The level of the mutation was calculated as the average variant ratio for each mutant from all
sequencing methods.most precise technique for identifying true heterozygosity.
In comparison, WGS showed an allelic ratio of 50.5 5
8.9%, and Sanger sequencing had a ratio of 51.4 5 8.7%
(Table S2). On the basis of the obtained distributions for
the allelic ratio, we determined that de novo mutations
with an allelic ratio below 32.8% for WGS, 39.3% for
ADS, and 33.9% for Sanger sequencing had a statistically
significant deviation from the expected ratio for true het-
erozygous mutations and might, as such, reflect mosaic
mutations.
Identification of Post-zygotic De Novo Mutations in
Probands
Our next objective was to determine the proportion of
post-zygotic events among a subset of de novo mutations
in our cohort. For this, we studied a pre-defined set of
107 de novo mutations by using WGS, ADS, and Sanger
sequencing (Figure 1B).21 As we did for the inherited vari-
ants, we determined each mutation’s allelic ratio for each
sequencing technique. After calculation of themean allelic
ratio across the three sequencing techniques, nine de novo
mutations showed a statistically significant deviation from
the expected ratio for true germline heterozygosity (Figures
S4 and S5). To exclude technical artifacts resulting from
biased allele amplification during PCR, which would
thereby falsely suggest the presence of mosaicism, we
generated a second independent amplicon with different
PCR primers to re-sequence all nine mutations by ADS
(Tables 1, S1, and S3). This analysis confirmed a statisti-
cally significant deviation in the allelic ratio for eight out
of nine de novo mutations. Of note, three of these muta-
tions had been previously reported as possible mosaic
mutations.21
To validate these findings with an independent test, we
set out to sequence the eight candidate mosaic mutations
by using smMIPs for increased depth and accuracy. By
sequencing germline mutations within the same assay,
we first established for this technique the average and
SD of the allelic ratio for true heterozygosity—this was
shown to be 47.1 5 3.3%. Unique smMIPs could be70 The American Journal of Human Genetics 97, 67–74, July 2, 2015designed for all but one candidate mosaic event, located
in an intron of SETBP1 (OMIM: 611060). The remaining
seven mutations were tested and confirmed to be present
as mosaic events with allelic ratios between 20.8% and
29.7%. Translating these allelic ratios into percentages of
cells carrying the mutation predicted that the mutations
must be present in 41.6%–59.4% of the cells in blood.
Thus, our results indicate that at least 7/107 (6.5%) de
novo mutations detected in our cohort did not occur in
the germline of the parent but instead arose post-zygoti-
cally in the offspring.
Parental Mosaicism as a Source of Seemingly De Novo
Mutations
Gonadal mosaicism in a healthy parent can lead to the
transmission of disease-causing mutations and recurrence
of disorders with seemingly de novo ocurrence.24 In
some cases, mosaicism might not be restricted to the
germ cells; it was recently shown that healthy individuals
with gonadal mosaicism for disease-causing CNVs, re-
vealed by recurrence of the disease in the offspring, carried
low levels of mosaicism for this CNV in blood.25 Following
this idea, we aimed to determine whether any of the seem-
ingly germline de novo events in our cohort of 50 pro-
bands had actually occurred as somatic mutations in one
of the parents (Figure 1C). For this, we re-analyzed all
4,081 high-confidence de novo mutations previously de-
tected by WGS in the probands and selected those de
novo mutations in which two or more variant reads could
be detected in the raw sequence data in one of the respec-
tive parents. Thirteen such mutations were identified, but
two could not be amplified by PCR andwere excluded from
further analysis. We performed ADS on the remaining 11
mutations to determine whether we could detect the
variant in DNA from the carrier parent. After stringent
correction for the background sequencing error, four of
these mutations were confirmed to be present in the blood
of one of the parents. These low-level parental mosaic mu-
tations showed an average allelic ratio of 3.54% (range
0.22%—6.15%; Tables 2 and S4). Of note, these low-level
Table 2. De Novo Mutations Originating from Parental Mosaicism
Genomic Location Gene OMIM Accession Number Gene Location Origin Total Reads (ADS) Variant Reads p Valuea
chr13:78303535A>T SLAIN1 610491 intron father 31,470 6.15% <0.001
chr18:25210178C>T – – intergenic father 34,149 2.56% <0.001
chr5:11327458C>T CTNND2 604275 intron mother 12,754 5.25% <0.001
chr5:147855052G>A HTR4 602164 intron father 20,927 0.22% <0.05
ap values were corrected for multiple testing by Bonferroni correction.parental mosaic mutations, of which three were trans-
mitted by the father and one by the mother, were not
detected in the parental DNA by Sanger sequencing
(Figure S6).
Modeling the Effect of Sequence Coverage on the
Detection of Mosaic Mutations
Evidently, sufficient sequencing coverage is required for
reliably identifying mosaic mutations. To investigate the
impact of coverage on the detection of mosaic mutations,
we modeled the probability of detecting both post-zygotic
mutations in a proband and low-level parental mosaicism
given different sequencing coverage.
The detection of post-zygotic de novo mutations re-
quires two essential steps: calling the variant in the pro-
band and identifying a significant deviation of the allelic
distribution. Modeling under the assumption that R5
variant reads are required for variant calling and that these
constituteR5% of the total number of sequence reads in-
dicates that at least 100-fold coverage is required for calling
90% of mosaic variants with an allelic ratio equal to 10%
or higher (Figure S7). Increased sequencing coverage de-
creases the SD in the allelic ratio, which reduces technical
variation (Figure S8) and allows for better discrimination
between true heterozygosity and mosaicism. Provided
that a post-zygotic mutation is called, we also modeled
the required deviation in the allelic ratio of a mosaic
variant for it to be reliably distinguished from a heterozy-
gous variant (Figure S9). Our model indicated that at least
100-fold coverage is required for distinguishing mosaic
mutations with allelic ratios < 40% from germline muta-
tions with 95% probability.
The analysis for parental mosaicism for de novo muta-
tions identified in a proband requires a different approach;
the identification of parental mosaicism for a seemingly de
novo mutation in the offspring is guided by the presence
of the variant in the proband. As a consequence, the
only requirement for the identification of parental mosai-
cism is to distinguish the variant reads in the parent
from the background sequencing error at the respective
genomic location. Under the assumption that two variant
reads in the parent are sufficient for this, we modeled the
coverage required for identifying low-level parental mosa-
icism (Figure S10), which showed that at least 140-fold
coverage is needed for detecting low-level mosaicism of
R5% withR95% probability.ThDiscussion
The aimof our studywas to investigate the presence of non-
germline events among de novo mutations. Our results
show that 6.5% (7/107) of a subset of de novo mutations
were present as mosaic mutations in the blood of the pro-
band, strongly suggestive of a post-zygotic origin. Extrapo-
lating our results to published genome-wide de novomuta-
tion rates3,21 suggests that each individual carries at least
two to sevendenovomutationsofpost-zygoticorigin.Addi-
tionally, froma group of 4,081mutations presumed to be de
novo in the offspring, we detected fourmutations that were
in fact inherited fromone of the parents inwhom themuta-
tion was present as a low-level mosaic mutation. Although
this represents only 0.1% of all high-quality de novo muta-
tions, parentalmosaicism for a seemingly denovomutation
in the offspringwas observed in 4 out of 50 trios. On the ba-
sisof the stringentcriteria thatweused tovalidatevariants as
mosaics and our modeling data, we anticipate that our re-
sults aremost likely an underestimation of the true number
of mosaic mutations present in blood.
Our initial selection of potential mosaic variants was
based on results obtained with relatively high-coverage
(80-fold) WGS. We have shown that, for trio-based WGS,
80-fold sequencing coverage is sufficient for identifying
post-zygotic events among de novo mutations. However,
statistical modeling of the probability of detecting mosai-
cism given various sequencing depths showed that, with
this coverage, there is only an 80%probability of obtaining
sufficient reads for identifyingmosaicism present inR10%
of the alleles (corresponding toR20% of the cells studied;
Figure S7). Similarly, with this coverage, we were only able
to reliably distinguish somatic events with allelic ratios
below 39% from germline mutations (Figure S9). This sug-
gests that post-zygotic variants with allelic ratios at either
extreme in the proband could have gone unidentified in
our study. On the other hand, the probability of obtaining
at least two sequence reads for identifying R5% parental
mosaicism is only 78% with 80-fold sequencing coverage,
suggesting that the identification of these mutations
can also be optimized by higher-sequencing coverage
(Figure S10). Indeed, the low-level parental mosaic variants
identified in our study had a significantly higher
sequencing depth in the carrier parent than did the other
de novo or post-zygotic mutations studied (Figure S11).
Our results and statistical modeling highlight thee American Journal of Human Genetics 97, 67–74, July 2, 2015 71
importance of high sequencing coverage in the design of
trio-based WGS studies. Currently, most WGS studies are
performed at 30-fold coverage.13,26,27 If we assume that
sequence quality is comparable to that of our study, this en-
tails that fewer than 20% of mosaic variants with an allelic
ratio between 10% and 33% can be identified with 30-fold
sequencing coverage. Additionally, at this sequencing
coverage, onlymosaicmutations with an allelic ratio below
35% can be reliably distinguished from true heterozygous
variants. Furthermore, our modeling suggests that there is
less than a 20% probability of identifying parental mosai-
cism with an allelic ratio of less than 5% with WGS at 30-
fold coverage. Given these results, our findings underline
the need for increased sequencing coverage in WGS for
the accurate identification of mosaicism.
Despite the aforementioned limitations, we have shown
thatWGS is a powerful method for genome-wide discovery
of mosaic events. In this study, we used three additional
techniques to confirmmosaicismof SNVs. After identifying
denovomutationsbyWGS,wefirst evaluated their status as
post-zygotic events by ADS and Sanger sequencing. A limi-
tation of both of these techniques is that they might show
an allelic imbalance as a result of biased amplification of
one allele over the other.28 For themost part, significant de-
viations in the allelic ratio secondary to technical artifacts
observed in Sanger sequencing and ADS were method-spe-
cific rather than reproducible PCR artifacts (Figure S12).We
have attempted to remedy this problem by using smMIPs,
which provide targeted high sequence coverage and the
ability to identify individual captured molecules23 and
thus prevent any allelic-ratio deviations resulting from
PCR amplification bias.
The presence of parental gonosomal mosaicism as the
cause of a sporadic disorder in a family places the subse-
quent offspring at higher risk for recurrence of the disease
than when the mutation is caused by a germline de novo
mutation.29 Considering this, the presence of parental
mosaicism in 4 out of 50 individuals of our cohort stresses
the importance of a thorough follow-up in families affected
by a disorder due to a de novo mutation.30 Notably, the
lower limit of detection by Sanger sequencing has been re-
ported to be close to only 10%,25 whereas the highest level
of parental mosaicism here detected was only 6.15% and
could not be identified by Sanger sequencing (Figure S6).
Because Sanger sequencing is commonly used in diagnos-
tics, parental mosaicism below the threshold of detection
of this method could account for recurrence of de novo dis-
orders within families24,31 and explain unsolved pedigrees
with an apparently recessive inheritance of disorders other-
wise known to be dominant.32 Under these circumstances,
high-coverage next-generation sequencing should be
favored over Sanger sequencing for the detection of low-
level parental mosaicism and might even be warranted as
a standard follow-up test for each pathogenic de novo mu-
tation. Related to this, the frequent detection of mosaic
events might partially explain the occurrence of known
dominant pathogenic mutations within large-scale variant72 The American Journal of Human Genetics 97, 67–74, July 2, 2015databases of healthy individuals, such as the NHLBI Exome
Sequencing Project Exome Variant Server. This point needs
to be taken into account when these databases are used for
clinical interpretation of possible pathogenic mutations.
Also, previous studies have shown that certain mutations
found as true heterozygous events in one tissue could be de-
tected at low levels or be completely absent in another.33
Clearly, further studies of mosaic mutations and their
impact on phenotypic variation require an in-depth anal-
ysis of different tissues.
In summary, our results show that a proportion of de
novo mutations presumed to be germline actually either
occurred post-zygotically in the offspring or were inherited
from low-level mosaicism in one of the parents. This indi-
cates that de novo mutations do not arise solely during
gametogenesis but also as post-zygotic mutations, suggest-
ing that our genomes might be much more dynamic than
previously considered. As the contribution of de novo mu-
tations to human disease becomes increasingly apparent,
this conclusion might very well have clinical implications.
Pathogenic variants in the mosaic state require particular
attention as to their detection via sequencing methods.
Furthermore, their influence on the risk of recurrence of
a disease underlines the importance of identifying mosai-
cism to offer accurate genetic counseling in sporadic disor-
ders caused by de novo mutations.Supplemental Data
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